Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19548 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Eitan Kugler und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Aniline Compounds, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Patients with FLT3 ‐mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard‐of‐care for patients with R/R FLT3 ‐mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt‐ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib ( n = 19) and gilt‐ven ( n = 17) for R/R AML after intensive chemotherapy. Gilteritinib and gilt‐ven groups did not differ in terms of mCRc rates (53% and 65%, p = 0.51) and realization of allogeneic haematopoietic stem‐cell transplantation (HSCT, 47% and 35%, p = 0.5). Overall survival (OS) was comparable between groups, although a trend towards better OS was seen with gilt‐ven (12‐month OS 58.8% [95% CI 39.5%–87.6%]) versus gilteritinib (42.1% [95% CI 24.9%–71.3%] for gilteritinib). Early salvage with gilt‐ven versus any other gilteritinib‐based approach was associated with the best outcome ( p = 0.031). Combination therapy was associated with increased haematological toxicity. In summary, gilt‐ven did not improve remissions or HSCT‐realization rates in patients with R/R FLT3 ‐mutated AML as compared with gilteritinib and was associated with increased haematological toxicity. Although OS did not differ, a trend towards better survival was suggested with gilt‐ven and a survival benefit was shown for gilt‐ven approach when sequenced early for salvage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Haematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
- Institute of Haematology, Tel-Aviv Sourasky Medical Center (TLVMC), Tel-Aviv, Israel.
- Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
ORCID-Profile: Vladimir Vainstein, Liat Shargian, Chezi Ganzel, Yishai Ofran, Shai Shimony, Ofir Wolach
Zitieren
APA
Kugler, E., Cohen, I., Amitai, I., Ram, R., Frisch, A., Nachmias, B., Canaani, J., Moshe, Y., Krayem, B., Aumann, S., Henig, I., Vainstein, V., Shargian, L., Ganzel, C., Yeshurun, M., Levi, I., Raanani, P., Akria, L., Ofran, Y., …, & Wolach, O. (2024). Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19548
Vancouver
Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, et al. Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19548
BibTeX
@article{Kugler2024,
author = {Kugler, Eitan and Cohen, Inbar and Amitai, Irina and Ram, Ron and Frisch, Avraham and Nachmias, Boaz and Canaani, Jonathan and Moshe, Yakir and Krayem, Baher and Aumann, Shlomzion and Henig, Israel and Vainstein, Vladimir and Shargian, Liat and Ganzel, Chezi and Yeshurun, Moshe and Levi, Itay and Raanani, Pia and Akria, Luiza and Ofran, Yishai and Shimony, Shai and Wolach, Ofir},
title = {Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19548}
}
EUVIMED